ArticleMedical oncology (Northwood, London, England)2025
Antineoplastic potential of Kushneria avicenniae pigments via modulation of the BAX/BCL-2 axis and CASP-9 pathway in inducing G2/M arrest and apoptosis in liver and breast cancer.
Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanistic Insights into Honey-Mediated Antibacterial Activity Against Enterobacteriaceae: A Multifaceted Approach Targeting Membrane Integrity, Protein Synthesis, and Quorum Sensing Inhibition.Probiotics and antimicrobial proteins · 2026Article
- Advances in Synthetic Strategies for Microalgal Carotenoid Enhancement and Emerging Applications.Antioxidants (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since cancer continues to be a chief cause of disease and mortality worldwide, new and efficient treatment approaches are desperately needed. Natural substances have become a foremost source of bioactive molecules with intriguing cytotoxic effects, particularly those originating from microbes. The cytotoxic potential of pigments derived from the halophilic bacteria Kushneria avicenniae HA346018, which was isolated from mangrove environments, is investigated in this work. These pigments' cytotoxic, apoptotic, and cell cycle-modulating properties were assessed in human HepG2 and MCF-7 cell lines. Both cancer cell lines revealed a dose-dependent decrease in cell viability, indicating the pigment extract's potent cytotoxic effects in vitro. HepG2 and MCF-7 cells have computed IC50 values of 52.7 ± 3.8 µg/mL and 48.3 ± 4.1 µg/mL, respectively. Its notable selective cytotoxicity highlighted the pigment's potential as a targeted therapy, which revealed much less toxicity against normal WI-38 cells. A notable concentration of cells in the G2/M phase and a considerable change in cell cycle progression were seen by flow cytometric analysis, indicating the extract's potential to cause cell cycle arrest. The regulation of cyclin-dependent kinases (CDKs) and DNA damage response pathways was associated with this inhibition at the G2/M checkpoint. Moreover, Annexin V-FITC/PI labeling and subsequent flow cytometric analysis verified that the pigment caused both early and late apoptotic events. The mitochondrial mechanisms that mediated the apoptosis were the elevation of pro-apoptotic proteins like Bax and the downregulation of anti-apoptotic proteins like Bcl-2, which eventually led to caspase activation. These results establish Kushneria avicenniae pigments as a viable source of bioactive chemicals with therapeutic potential for breast and liver malignancies by offering new mechanistic insights into their apoptosis-inducing effect in cancer cell lines. This study encourages more investigation into natural compounds obtained from microorganisms as potential substitutes for traditional cancer therapies.
Indexed as
Identifiers
40753129What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.